

## Supplementary Material

### STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Lines 1 to 3, Page 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Lines 4 to 25, Page 1
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Lines 31 to 77, Pages 2 and 3
Objectives	3	State specific objectives, including any prespecified hypotheses	Lines 75 to 77, Page 3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Lines 80 to 88, Page 3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Lines 80 to 88, Page 3
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Lines 80 to 88, Page 3
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Lines 89 to 95, Pages 3 and 4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Lines 89 to 95, Pages 3 and 4
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	NA
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Lines 96 to 106, Page 4
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Lines 113 to 116, Page 4
		(b) Indicate number of participants with missing data for each variable of interest	NA

Outcome data	15*	Report numbers of outcome events or summary measures	Lines 117 to 195, Pages 4 to 6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Lines 117 to 195, Pages 4 and 5
		(b) Report category boundaries when continuous variables were categorized	Qualitative data synthesis
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Lines 199 and 205; lines 227 to 130; Across pages 7 and 8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Lines 247 to 252, Page 8
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Lines 199 and 205; lines 227 to 130; Across pages 7 and 8
Generalisability	21	Discuss the generalisability (external validity) of the study results	Lines 245 to 252, Page 8
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).